News

Sjögren’s Foundation Recognizes Volunteers

The Sjögren’s Foundation, a nonprofit health organization focused on increasing research, education, and awareness about Sjögren’s syndrome, has announced its most dedicated volunteers who were honored recently at the foundation’s 2021 Virtual National Patient Conference. “Every year, the Foundation recognizes our most dedicated volunteers through awards that are…

Foundation Awards Research Projects Focused on Diagnosis, Treatment

The Sjögren’s Foundation has awarded a total of $200,000 to four U.S. research projects focused on identifying diagnostic biomarkers and improving treatment of Sjögren’s syndrome. The foundation’s Research Grants Program “places a high priority on both clinical and basic scientific research into the cause, prevention, detection, treatment, and cure…

Study: Salivary Gland Biopsy Is Safe Diagnostic Method

A salivary gland biopsy on the lower lip may be considered a safe procedure for diagnosing Sjögren’s syndrome, with relatively few and mild complications, a study found. According to its authors, proper management and follow-up may reduce the risk of complications from the biopsy and help in the recovery…

Third COVID Vaccine Recommended for Most Patients

To combat the continued spread of COVID-19 and its Delta variant, Sjögren’s syndrome patients should get a third dose of the Pfizer or Moderna vaccine, the Sjögren’s Foundation has recommended, pursuant to Centers for Disease Control and Prevention (CDC) guidelines. The CDC — the United States’ public…

Better Treatment Recommendations Needed for Children

Current studies investigating treatment strategies for children with Sjögren’s syndrome have poor quality evidence for the development of clinical recommendations, a recent study has found. As such, these children are still prescribed medication based on their doctors’ opinions, not on evidence-based treatment recommendations. “Future research is required to guide…

Rituximab Safe, Effective in Case of Sjogren’s-related ILD

Rituximab safely and effectively treated sudden interstitial lung disease (ILD) in a 49-year-old man with undiagnosed primary Sjögren’s syndrome, a case study shows. This case adds to a growing number of reports and case series showing that rituximab lessens lung involvement in Sjögren’s patients, further supporting the usefulness…